ArticleJournal of the American Heart Association2026
Implications of the 2024 American Heart Association Classification of Cardiac Sarcoidosis: Characteristics and Outcome of Patients Across the Continuum of Diagnostic Likelihood.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is no universal agreement on the diagnostic criteria for cardiac sarcoidosis (CS). In 2024, the American Heart Association (AHA) introduced a new diagnostic scheme featuring a quaternary likelihood stratification for CS instead of dichotomy. Its clinical implications are unknown.
methodsWe analyzed 252 patients with CS and proven histology (mean age, 49 years; 61% women). Following the AHA diagnostic stratification, CS was retrospectively considered definite given sarcoid granulomas on myocardial biopsy (n=109), highly probable with both clinical and cardiac imaging findings being CS consistent (n=93), and probable with either clinical or imaging findings alone being CS consistent (n=50). The groups were compared for clinical characteristics and the composite incidence of death, transplantation, implantation of a left ventricular assist device, and ventricular tachyarrhythmia on follow-up (median, 5.0 years).
resultsIn AHA definite, highly probable, and probable CS: 94%, 99%, and 22% of patients (
conclusionsThe 2024 AHA stratification of CS likelihood distinguishes groups with differences in clinical characteristics but did not have independent prognostic value in our statistical analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.